456 related articles for article (PubMed ID: 24968045)
41. Primary dapsone resistance in Cebu, The Philippines; cause for concern.
dela Cruz E; Cellona RV; Balagon MV; Villahermosa LG; Fajardo TT; Abalos RM; Tan EV; Walsh GP
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):253-6. PubMed ID: 8862258
[TBL] [Abstract][Full Text] [Related]
42. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
43. Analysis of drug-resistant strains of Mycobacterium leprae in an endemic area of Vietnam.
Kai M; Nguyen Phuc NH; Nguyen HA; Pham TH; Nguyen KH; Miyamoto Y; Maeda Y; Fukutomi Y; Nakata N; Matsuoka M; Makino M; Nguyen TT
Clin Infect Dis; 2011 Mar; 52(5):e127-32. PubMed ID: 21292655
[TBL] [Abstract][Full Text] [Related]
44. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.
Shetty VP; Wakade AV; Ghate S; Pai VV; Ganapati R; Antia NH
Int J Lepr Other Mycobact Dis; 2003 Sep; 71(3):210-7. PubMed ID: 14608816
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
[TBL] [Abstract][Full Text] [Related]
46. Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis.
Li X; Li G; Yang J; Jin G; Shao Y; Li Y; Wei P; Zhang L
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293307
[TBL] [Abstract][Full Text] [Related]
47. Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy.
Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
Southeast Asian J Trop Med Public Health; 1997 Dec; 28(4):803-10. PubMed ID: 9656405
[TBL] [Abstract][Full Text] [Related]
48. Relapse with multibacillary leprosy caused by rifampicin sensitive organisms following paucibacillary multidrug therapy.
Soares DJ; Neupane K; Britton WJ
Lepr Rev; 1995 Sep; 66(3):210-3. PubMed ID: 7500815
[TBL] [Abstract][Full Text] [Related]
49. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
50. Drug-resistant leprosy: monitoring and current status.
Williams DL; Gillis TP
Lepr Rev; 2012 Sep; 83(3):269-81. PubMed ID: 23356028
[No Abstract] [Full Text] [Related]
51. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
52. Simultaneous detection of Mycobacterium leprae and its susceptibility to dapsone using DNA heteroduplex analysis.
Williams DL; Pittman TL; Gillis TP; Matsuoka M; Kashiwabara Y
J Clin Microbiol; 2001 Jun; 39(6):2083-8. PubMed ID: 11376039
[TBL] [Abstract][Full Text] [Related]
53. Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
J Med Assoc Thai; 1996 Apr; 79(4):210-7. PubMed ID: 8708505
[TBL] [Abstract][Full Text] [Related]
54. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
55. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
[TBL] [Abstract][Full Text] [Related]
56. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
[TBL] [Abstract][Full Text] [Related]
57. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy.
Cambau E; Bonnafous P; Perani E; Sougakoff W; Ji B; Jarlier V
Clin Infect Dis; 2002 Jan; 34(1):39-45. PubMed ID: 11731943
[TBL] [Abstract][Full Text] [Related]
58. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy.
Cambau E; Carthagena L; Chauffour A; Ji B; Jarlier V
Clin Infect Dis; 2006 Jan; 42(2):238-41. PubMed ID: 16355335
[TBL] [Abstract][Full Text] [Related]
59. Antimicrobial Resistance among Leprosy Patients in Brazil: Real-World Data Based on the National Surveillance Plan.
Andrade ESN; Brandão JG; Silva JSD; Coriolano CRF; Rosa PS; Moraes MO; Ferreira CO; Gomes CM; Araújo WN
Antimicrob Agents Chemother; 2022 May; 66(5):e0217021. PubMed ID: 35435708
[TBL] [Abstract][Full Text] [Related]
60. Mutation at codon 442 in the rpoB gene of Mycobacterium leprae does not confer resistance to rifampicin.
Lavania M; Hena A; Reja H; Nigam A; Biswas NK; Singh I; Turankar RP; Gupta U; Kumar S; Rewaria L; Patra PK; Sengupta U; Bhattacharya B
Lepr Rev; 2016 Mar; 87(1):93-100. PubMed ID: 27255062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
